This educational resource is independently supported by AbbVie. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. 

During the 30th European Hematology Association (EHA) Congress, the Lymphoma Hub was pleased to speak to Marek Trněný, Charles University, Prague, CZ. We asked, How effective is epcoritamab + R-ICE in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are eligible for autologous stem cell transplantation (ASCT)? 

In this interview, Trněný shares the first efficacy and safety data from the phase I/II EPCORE NHL-2 trial (NCT04663347) of epcoritamab + R-ICE in patients with R/R DLBCL. Trněný concludes that the encouraging data support the viability of using this combination for patients with R/R DLBCL who are eligible for ASCT. 

Hosted on Acast. See acast.com/privacy for more information.